Friday, November 21, 2008

CHMP Recommends Approval of New Indication for Enbrel as Treatment for Severe Psoriasis in Paediatric Patients

The European Committee for Medicinal Products for Human Use (CHMP) today announced its positive recommendation for the approval of Enbrel(R) (etanercept) as a treatment for children aged 8 years and over and adolescents with severe plaque psoriasis.

The details can be read here.

No comments: